Alessandro Gronchi Selected Research

Myxoid Liposarcoma

3/2020	Correction: Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas.
3/2020	Correction: Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin.
12/2019	Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas.
3/2019	Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups.
1/2019	Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin.
6/2017	Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implications.
1/2017	High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma.
1/2017	Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
6/2014	Emerging therapies for adult soft tissue sarcoma.
10/2010	Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alessandro Gronchi Research Topics

Disease

106	Neoplasms (Cancer) 05/2022 - 08/2003
95	Sarcoma (Soft Tissue Sarcoma) 07/2022 - 08/2004
20	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2022 - 07/2004
17	Liposarcoma 07/2022 - 07/2007
17	Neoplasm Metastasis (Metastasis) 05/2022 - 08/2004
13	Myxoid Liposarcoma 03/2020 - 07/2007
11	Leiomyosarcoma 01/2022 - 12/2010
9	Aggressive Fibromatosis (Desmoid) 01/2021 - 09/2007
7	Chordoma 10/2018 - 11/2004
6	Dermatofibrosarcoma 01/2017 - 10/2005
5	Fibroma (Fibromatosis) 01/2021 - 12/2015
5	Extraskeletal Myxoid Chondrosarcoma 12/2020 - 10/2012
5	Solitary Fibrous Tumors 01/2020 - 05/2010
5	Synovial Sarcoma (Synovioma) 06/2017 - 02/2004
4	Hyperthermia 07/2021 - 09/2002
4	Disease Progression 01/2021 - 09/2013
4	Neurofibrosarcoma (MPNST) 01/2020 - 09/2003
4	Pain (Aches) 01/2019 - 03/2012
3	Hemangiosarcoma (Angiosarcoma) 01/2022 - 06/2014
3	Alveolar Soft Part Sarcoma 06/2014 - 02/2009
2	Pancreatic Neoplasms (Pancreatic Cancer) 10/2021 - 07/2017
2	Chondrosarcoma 12/2020 - 01/2019
2	Perivascular Epithelioid Cell Neoplasms 10/2020 - 01/2019
2	Neutropenia 01/2020 - 01/2017
2	Melanoma (Melanoma, Malignant) 03/2019 - 02/2012
2	Infections 03/2019 - 01/2019
2	Retroperitoneal liposarcoma 01/2019 - 12/2010
2	Inflammation (Inflammations) 11/2017 - 09/2011
2	Neurofibromatosis 1 (Neurofibromatosis Type I) 01/2017 - 12/2009
2	Fibrosarcoma 06/2014 - 10/2011
2	Clear Cell Sarcoma 09/2013 - 02/2012
2	Margins of Excision 02/2013 - 03/2010
2	Rare Diseases (Rare Disease) 03/2012 - 09/2002
2	Carcinoma (Carcinomatosis) 12/2010 - 09/2002
1	Adrenal Insufficiency (Adrenal Gland Hypofunction) 01/2022
1	Lymphoma (Lymphomas) 12/2021

Drug/Important Bio-Agent (IBA)

32	Imatinib Mesylate (Gleevec)FDA Link 01/2022 - 07/2004
17	TrabectedinIBA 03/2021 - 07/2007
16	Ifosfamide FDA LinkGeneric 12/2021 - 01/2014
12	Biological ProductsIBA 01/2022 - 08/2007
10	AnthracyclinesIBA 01/2022 - 12/2013
10	Proteins (Proteins, Gene)FDA Link 06/2020 - 07/2007
8	Doxorubicin (Adriamycin)FDA LinkGeneric 03/2021 - 05/2004
8	Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)IBA 11/2015 - 11/2004
8	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 03/2012 - 02/2004
7	Pharmaceutical PreparationsIBA 01/2021 - 09/2002
7	Gemcitabine FDA Link 01/2020 - 06/2014
6	Tyrosine Kinase InhibitorsIBA 08/2019 - 07/2004
5	Sunitinib (Sutent)FDA Link 06/2018 - 02/2009
5	Phosphotransferases (Kinase)IBA 01/2015 - 02/2004
4	CateninsIBA 01/2021 - 10/2013
4	Dacarbazine (DIC)FDA LinkGeneric 01/2020 - 06/2014
4	pazopanib FDA Link 01/2020 - 06/2014
4	Proto-Oncogene Proteins c-sis (Platelet Derived Growth Factor B)IBA 11/2015 - 09/2007
4	Platelet-Derived Growth FactorIBA 03/2012 - 10/2005
4	LigandsIBA 08/2010 - 02/2004
3	Dihydrotachysterol (AT 10)IBA 01/2022 - 10/2005
3	MTOR InhibitorsIBA 10/2020 - 08/2010
3	Etoposide (VP 16)FDA LinkGeneric 01/2020 - 01/2017
3	Epirubicin (Ellence)FDA LinkGeneric 06/2017 - 11/2015
3	Telomerase (Telomerase Reverse Transcriptase)IBA 06/2012 - 09/2006
2	nilotinib FDA Link 12/2021 - 05/2013
2	multidrug resistance-associated protein 1IBA 12/2021 - 01/2014
2	Methotrexate (Mexate)FDA LinkGeneric 01/2021 - 03/2017
2	Vinca AlkaloidsIBA 01/2021 - 03/2017
2	Hormones (Hormone)IBA 11/2020 - 01/2019
2	Gonadotropin-Releasing Hormone (GnRH)FDA Link 10/2020 - 01/2019
2	Sirolimus (Rapamycin)FDA Link 10/2020 - 01/2016
2	Pioglitazone (Actos)FDA Link 03/2020 - 12/2019
2	Docetaxel (Taxotere)FDA Link 01/2020 - 01/2017
2	TOR Serine-Threonine KinasesIBA 10/2018 - 12/2009
2	Biomarkers (Surrogate Marker)IBA 10/2018 - 11/2017
2	Formaldehyde (Formol)FDA Link 01/2016 - 08/2010
2	beta CateninIBA 01/2016 - 09/2007
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 05/2013 - 03/2012
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 02/2012 - 02/2004
2	Complement System Proteins (Complement)IBA 05/2009 - 07/2007
1	AZD 6244IBA 12/2021
1	avapritinibIBA 12/2021
1	ripretinibIBA 12/2021
1	selinexorIBA 03/2021
1	SurvivinIBA 03/2021

Therapy/Procedure

49	Drug Therapy (Chemotherapy) 01/2022 - 08/2004
37	Therapeutics 04/2022 - 08/2003
35	Radiotherapy 07/2022 - 06/2007
19	Neoadjuvant Therapy 05/2022 - 09/2013
7	Adjuvant Chemotherapy 01/2022 - 08/2004
4	Pancreatectomy 03/2022 - 03/2011
3	Surgical Amputation (Amputations) 01/2022 - 12/2007
3	Hyperthermic Intraperitoneal Chemotherapy 04/2021 - 12/2010
3	Cytoreduction Surgical Procedures 04/2021 - 09/2002
3	Operative Surgical Procedures 02/2021 - 01/2018
3	Catheters 03/2019 - 01/2016
3	Molecular Targeted Therapy 12/2010 - 11/2004
2	Immunotherapy 01/2022 - 01/2017
2	Morcellation 11/2020 - 05/2016
2	Precision Medicine 01/2020 - 08/2017
1	Adrenalectomy 01/2022
1	Chemoradiotherapy 01/2021
1	Re-Irradiation 12/2020